- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04628767
Testando a adição de MEDI4736 (Durvalumab) à quimioterapia antes da cirurgia para pacientes com câncer de trato urinário superior de alto grau
Um estudo de fase II/III do MEDI4736 (Durvalumabe) e quimioterapia para pacientes com câncer urotelial do trato superior de alto grau antes da nefroureterectomia
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
Visão geral do estudo
Status
Intervenção / Tratamento
- Medicamento: Cisplatin
- Procedimento: Biospecimen Collection
- Medicamento: Methotrexate
- Procedimento: Computed Tomography
- Procedimento: Magnetic Resonance Imaging
- Medicamento: Gemcitabine Hydrochloride
- Procedimento: Therapeutic Conventional Surgery
- Procedimento: Biopsy Procedure
- Biológico: Durvalumab
- Medicamento: Doxorubicin Hydrochloride
- Biológico: Pegfilgrastim
- Medicamento: Vinblastine Sulfate
Descrição detalhada
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with upper tract urothelial cancer (UTUC) randomized to neoadjuvant accelerated methotrexate, vinblastine, Adriamycin, cisplatin (aMVAC) alone or in combination with durvalumab. (Cisplatin eligible patients [Arms A and B]) II. Evaluation of pathologic complete response at radical nephroureterectomy (RNU) (pathologic complete response [pCR], ypT0N0/Nx). (Cisplatin ineligible patients [Arm C]).
SECONDARY OBJECTIVES:
I. To assess pathologic complete response (pCR) at surgery. (Cisplatin eligible cohort) II. Event-free survival (EFS) will be evaluated for the cisplatin ineligible cohort as a secondary endpoint. (Cisplatin ineligible cohort) III. Overall survival in all, and by post chemotherapy response (ypT0N0, yp =< T1N0, yp >= T2Nany). (All patients) IV. To evaluate disease-free survival (DFS) in each arm of the trial separately. (All patients) V. To evaluate cancer-specific survival of patients in each arm of the trial separately. (All patients) VI. To evaluate renal function outcomes following systemic treatment and following surgery ([RNU) in each arm of the trial separately. (All patients) VII. To evaluate safety and tolerability of neoadjuvant aMVAC alone or in combination with durvalumab prior to RNU. (All patients)
OUTLINE: Patients eligible for cisplatin are randomized to Arms A or B. Patients ineligible for cisplatin are assigned to Arm C.
ARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM B: Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
ARM C: Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery.
Patients also undergo tissue biopsy and blood sample collection on study, and computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
After completion of study treatment, patients are followed up within 30 days and then every 3-6 months for up to 5 years from study entry.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Kingman, Arizona, Estados Unidos, 86401
- Recrutamento
- Kingman Regional Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 702-384-0013
- E-mail: research@sncrf.org
-
Investigador principal:
- Khawaja S. Jahangir
-
-
Arkansas
-
Fort Smith, Arkansas, Estados Unidos, 72903
- Suspenso
- Mercy Hospital Fort Smith
-
Little Rock, Arkansas, Estados Unidos, 72205
- Ativo, não recrutando
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Estados Unidos, 95602
- Ativo, não recrutando
- Sutter Auburn Faith Hospital
-
Berkeley, California, Estados Unidos, 94704
- Ativo, não recrutando
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Estados Unidos, 91010
- Ativo, não recrutando
- City of Hope Comprehensive Cancer Center
-
Fremont, California, Estados Unidos, 94538
- Ativo, não recrutando
- Palo Alto Medical Foundation-Fremont
-
La Jolla, California, Estados Unidos, 92093
- Recrutamento
- UC San Diego Moores Cancer Center
-
Investigador principal:
- Aditya Bagrodia
-
Contato:
- Site Public Contact
- Número de telefone: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Modesto, California, Estados Unidos, 95355
- Ativo, não recrutando
- Memorial Medical Center
-
Mountain View, California, Estados Unidos, 94040
- Ativo, não recrutando
- Palo Alto Medical Foundation-Camino Division
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Stanford Cancer Institute Palo Alto
-
Investigador principal:
- Ali R. Khaki
-
Contato:
- Site Public Contact
- Número de telefone: 650-498-7061
- E-mail: cancertrialsinfo@stanford.edu
-
Palo Alto, California, Estados Unidos, 94301
- Ativo, não recrutando
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Estados Unidos, 95661
- Ativo, não recrutando
- Sutter Roseville Medical Center
-
Sacramento, California, Estados Unidos, 95816
- Ativo, não recrutando
- Sutter Medical Center Sacramento
-
San Diego, California, Estados Unidos, 92103
- Recrutamento
- UC San Diego Medical Center - Hillcrest
-
Investigador principal:
- Aditya Bagrodia
-
Contato:
- Site Public Contact
- E-mail: rhabbaba@health.ucsd.edu
-
San Francisco, California, Estados Unidos, 94115
- Ativo, não recrutando
- California Pacific Medical Center-Pacific Campus
-
Santa Cruz, California, Estados Unidos, 95065
- Ativo, não recrutando
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Estados Unidos, 95403
- Ativo, não recrutando
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Estados Unidos, 94086
- Ativo, não recrutando
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Estados Unidos, 94589
- Ativo, não recrutando
- Sutter Solano Medical Center/Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Recrutamento
- UCHealth University of Colorado Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 720-848-0650
-
Investigador principal:
- Elizabeth R. Kessler
-
Denver, Colorado, Estados Unidos, 80206
- Recrutamento
- UCHealth - Cherry Creek
-
Contato:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Investigador principal:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Estados Unidos, 80524
- Recrutamento
- Poudre Valley Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 970-297-6150
-
Investigador principal:
- Elizabeth R. Kessler
-
Fort Collins, Colorado, Estados Unidos, 80528
- Recrutamento
- Cancer Care and Hematology-Fort Collins
-
Contato:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Investigador principal:
- Elizabeth R. Kessler
-
Greeley, Colorado, Estados Unidos, 80631
- Recrutamento
- UCHealth Greeley Hospital
-
Contato:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Investigador principal:
- Elizabeth R. Kessler
-
Highlands Ranch, Colorado, Estados Unidos, 80129
- Recrutamento
- UCHealth Highlands Ranch Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 720-848-0650
-
Investigador principal:
- Elizabeth R. Kessler
-
Lone Tree, Colorado, Estados Unidos, 80124
- Recrutamento
- UCHealth Lone Tree Health Center
-
Contato:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Investigador principal:
- Elizabeth R. Kessler
-
Loveland, Colorado, Estados Unidos, 80538
- Recrutamento
- Medical Center of the Rockies
-
Contato:
- Site Public Contact
- Número de telefone: 970-203-7083
-
Investigador principal:
- Elizabeth R. Kessler
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20016
- Recrutamento
- Sibley Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 202-243-2373
- E-mail: jquiver1@jhmi.edu
-
Investigador principal:
- Jean H. Hoffman-Censits
-
Washington D.C., District of Columbia, Estados Unidos, 20010
- Recrutamento
- MedStar Washington Hospital Center
-
Contato:
- Site Public Contact
- Número de telefone: 202-877-8839
-
Investigador principal:
- Suthee Rapisuwon
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Ativo, não recrutando
- Mayo Clinic in Florida
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University Hospital/Winship Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 404-778-1868
-
Investigador principal:
- Jacqueline T. Brown
-
Atlanta, Georgia, Estados Unidos, 30308
- Recrutamento
- Emory University Hospital Midtown
-
Contato:
- Site Public Contact
- Número de telefone: 888-946-7447
-
Investigador principal:
- Jacqueline T. Brown
-
Atlanta, Georgia, Estados Unidos, 30342
- Recrutamento
- Emory Saint Joseph's Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 404-851-7115
-
Investigador principal:
- Jacqueline T. Brown
-
Decatur, Georgia, Estados Unidos, 30033
- Recrutamento
- Emory Decatur Hospital
-
Investigador principal:
- Jacqueline T. Brown
-
Contato:
- Site Public Contact
- Número de telefone: 440-778-1868
- E-mail: clinicaltrialsoncology@dekalbmedical.org
-
-
Idaho
-
Nampa, Idaho, Estados Unidos, 83687
- Recrutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Investigador principal:
- Elie G. Dib
-
-
Illinois
-
Alton, Illinois, Estados Unidos, 62002
- Suspenso
- OSF Saint Anthony's Health Center
-
Barrington, Illinois, Estados Unidos, 60010
- Recrutamento
- Advocate Good Shepherd Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-842-4847
-
Investigador principal:
- Thomas J. Saphner
-
Bloomington, Illinois, Estados Unidos, 61704
- Ativo, não recrutando
- Illinois CancerCare-Bloomington
-
Burr Ridge, Illinois, Estados Unidos, 60527
- Ativo, não recrutando
- Loyola Center for Health at Burr Ridge
-
Canton, Illinois, Estados Unidos, 61520
- Ativo, não recrutando
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Estados Unidos, 62902
- Suspenso
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Estados Unidos, 62918
- Recrutamento
- SIH Cancer Institute
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 618-985-3333
- E-mail: clinical.research@sih.net
-
Carthage, Illinois, Estados Unidos, 62321
- Ativo, não recrutando
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Suspenso
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60657
- Recrutamento
- Advocate Illinois Masonic Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 773-296-5360
-
Investigador principal:
- Thomas J. Saphner
-
Crystal Lake, Illinois, Estados Unidos, 60014
- Recrutamento
- AMG Crystal Lake - Oncology
-
Contato:
- Site Public Contact
- Número de telefone: 630-929-6129
- E-mail: advocateresearch@advocate.com
-
Investigador principal:
- Thomas J. Saphner
-
Danville, Illinois, Estados Unidos, 61832
- Recrutamento
- Carle at The Riverfront
-
Investigador principal:
- Prem Sobti
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@Carle.com
-
Decatur, Illinois, Estados Unidos, 62526
- Recrutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Estados Unidos, 62526
- Suspenso
- Decatur Memorial Hospital
-
Dixon, Illinois, Estados Unidos, 61021
- Ativo, não recrutando
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Estados Unidos, 60515
- Recrutamento
- Advocate Good Samaritan Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 630-275-1270
- E-mail: Barbara.barhamand@advocatehealth.com
-
Investigador principal:
- Thomas J. Saphner
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Carle Physician Group-Effingham
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Prem Sobti
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Crossroads Cancer Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Elgin, Illinois, Estados Unidos, 60123
- Recrutamento
- Advocate Sherman Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-429-2907
-
Investigador principal:
- Thomas J. Saphner
-
Eureka, Illinois, Estados Unidos, 61530
- Ativo, não recrutando
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Suspenso
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Estados Unidos, 61401
- Ativo, não recrutando
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Estados Unidos, 60429
- Recrutamento
- Advocate South Suburban Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 708-799-9995
-
Investigador principal:
- Thomas J. Saphner
-
Homer Glen, Illinois, Estados Unidos, 60491
- Ativo, não recrutando
- Loyola Medicine Homer Glen
-
Kewanee, Illinois, Estados Unidos, 61443
- Ativo, não recrutando
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Estados Unidos, 60048
- Recrutamento
- AMG Libertyville - Oncology
-
Contato:
- Site Public Contact
- Número de telefone: 630-929-6129
- E-mail: advocateresearch@advocatehealth.com
-
Investigador principal:
- Thomas J. Saphner
-
Macomb, Illinois, Estados Unidos, 61455
- Ativo, não recrutando
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Estados Unidos, 61938
- Recrutamento
- Carle Physician Group-Mattoon/Charleston
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Prem Sobti
-
Maywood, Illinois, Estados Unidos, 60153
- Ativo, não recrutando
- Loyola University Medical Center
-
Melrose Park, Illinois, Estados Unidos, 60160
- Ativo, não recrutando
- Marjorie Weinberg Cancer Center at Loyola-Gottlieb
-
Mount Vernon, Illinois, Estados Unidos, 62864
- Recrutamento
- SSM Health Good Samaritan
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 618-899-1894
- E-mail: gayla.hall@ssmhealth.com
-
O'Fallon, Illinois, Estados Unidos, 62269
- Recrutamento
- Cancer Care Center of O'Fallon
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Oak Lawn, Illinois, Estados Unidos, 60453-2699
- Recrutamento
- Advocate Christ Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-323-8622
-
Investigador principal:
- Thomas J. Saphner
-
Ottawa, Illinois, Estados Unidos, 61350
- Ativo, não recrutando
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Estados Unidos, 60068
- Recrutamento
- Advocate Lutheran General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 847-384-3621
-
Investigador principal:
- Thomas J. Saphner
-
Pekin, Illinois, Estados Unidos, 61554
- Ativo, não recrutando
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Suspenso
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61615
- Ativo, não recrutando
- Illinois CancerCare-Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Suspenso
- Valley Radiation Oncology
-
Peru, Illinois, Estados Unidos, 61354
- Ativo, não recrutando
- Illinois CancerCare-Peru
-
Princeton, Illinois, Estados Unidos, 61356
- Ativo, não recrutando
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Southern Illinois University School of Medicine
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-545-7929
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Springfield Clinic
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 800-444-7541
-
Springfield, Illinois, Estados Unidos, 62781
- Suspenso
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Recrutamento
- Carle Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Prem Sobti
-
Washington, Illinois, Estados Unidos, 61571
- Ativo, não recrutando
- Illinois CancerCare - Washington
-
-
Indiana
-
Richmond, Indiana, Estados Unidos, 47374
- Ativo, não recrutando
- Reid Health
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Ativo, não recrutando
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- Ativo, não recrutando
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Estados Unidos, 52722
- Recrutamento
- University of Iowa Healthcare Cancer Services Quad Cities
-
Investigador principal:
- Fernando Maciel Barbosa
-
Contato:
- Site Public Contact
- Número de telefone: 563-355-7733
- E-mail: katherine-daprile@uiowa.edu
-
Boone, Iowa, Estados Unidos, 50036
- Ativo, não recrutando
- McFarland Clinic - Boone
-
Fort Dodge, Iowa, Estados Unidos, 50501
- Ativo, não recrutando
- McFarland Clinic - Trinity Cancer Center
-
Iowa City, Iowa, Estados Unidos, 52242
- Recrutamento
- University of Iowa/Holden Comprehensive Cancer Center
-
Investigador principal:
- Fernando Maciel Barbosa
-
Contato:
- Site Public Contact
- Número de telefone: 800-237-1225
-
Jefferson, Iowa, Estados Unidos, 50129
- Ativo, não recrutando
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Estados Unidos, 50158
- Ativo, não recrutando
- McFarland Clinic - Marshalltown
-
-
Kansas
-
Garden City, Kansas, Estados Unidos, 67846
- Suspenso
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Estados Unidos, 67530
- Suspenso
- Central Care Cancer Center - Great Bend
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- Recrutamento
- University of Kentucky/Markey Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 859-257-3379
-
Investigador principal:
- Patrick J. Hensley
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Recrutamento
- Mary Bird Perkins Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 225-215-1353
- E-mail: clinicalresearch@marybird.com
-
Investigador principal:
- Victor T. Lin
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Investigador principal:
- Rajasree P. Chowdry
-
Metairie, Louisiana, Estados Unidos, 70006
- Suspenso
- East Jefferson General Hospital
-
Metairie, Louisiana, Estados Unidos, 70002
- Recrutamento
- Mary Bird Perkins Cancer Center - Metairie
-
Investigador principal:
- Victor T. Lin
-
Contato:
- Site Public Contact
- Número de telefone: 504-584-6990
-
New Orleans, Louisiana, Estados Unidos, 70112
- Recrutamento
- University Medical Center New Orleans
-
Contato:
- Site Public Contact
- Número de telefone: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Investigador principal:
- Rajasree P. Chowdry
-
-
Maine
-
Augusta, Maine, Estados Unidos, 04330
- Recrutamento
- Harold Alfond Center for Cancer Care
-
Contato:
- Site Public Contact
- Número de telefone: 207-626-4855
-
Investigador principal:
- Erin Adler
-
Biddeford, Maine, Estados Unidos, 04005
- Suspenso
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Estados Unidos, 04073
- Recrutamento
- MaineHealth Cancer Care Center of York County
-
Contato:
- Site Public Contact
- Número de telefone: 207-459-1600
-
Investigador principal:
- Erin Adler
-
Sanford, Maine, Estados Unidos, 04073
- Recrutamento
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Investigador principal:
- Erin Adler
-
Scarborough, Maine, Estados Unidos, 04074
- Recrutamento
- MaineHealth Maine Medical Center- Scarborough
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Investigador principal:
- Erin Adler
-
South Portland, Maine, Estados Unidos, 04106
- Recrutamento
- MaineHealth Cancer Care and IV Therapy - South Portland
-
Contato:
- Site Public Contact
- Número de telefone: 207-396-8670
- E-mail: clinicalresearch@mainehealth.org
-
Investigador principal:
- Erin Adler
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 410-955-8804
- E-mail: jhcccro@jhmi.edu
-
Investigador principal:
- Jean H. Hoffman-Censits
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01655
- Recrutamento
- UMass Memorial Medical Center - University Campus
-
Contato:
- Site Public Contact
- Número de telefone: 508-856-3216
- E-mail: cancer.research@umassmed.edu
-
Investigador principal:
- Kriti Mittal
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Recrutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Brighton, Michigan, Estados Unidos, 48114
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Brighton, Michigan, Estados Unidos, 48114
- Recrutamento
- Trinity Health Medical Center - Brighton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Canton, Michigan, Estados Unidos, 48188
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Canton, Michigan, Estados Unidos, 48188
- Recrutamento
- Trinity Health Medical Center - Canton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Chelsea, Michigan, Estados Unidos, 48118
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Chelsea, Michigan, Estados Unidos, 48118
- Recrutamento
- Chelsea Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Clarkston, Michigan, Estados Unidos, 48346
- Recrutamento
- Hematology Oncology Consultants-Clarkston
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Clarkston, Michigan, Estados Unidos, 48346
- Suspenso
- Newland Medical Associates-Clarkston
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Genesys Hurley Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Elie G. Dib
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Hurley Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Elie G. Dib
-
Flint, Michigan, Estados Unidos, 48503
- Suspenso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Cancer Hematology Centers - Flint
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Elie G. Dib
-
Livonia, Michigan, Estados Unidos, 48154
- Suspenso
- Hope Cancer Clinic
-
Livonia, Michigan, Estados Unidos, 48154
- Recrutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Macomb, Michigan, Estados Unidos, 48044
- Recrutamento
- Henry Ford Saint John Hospital - Macomb Medical
-
Investigador principal:
- Elie G. Dib
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Michigan Healthcare Professionals Pontiac
-
Investigador principal:
- Elie G. Dib
-
Contato:
- Site Public Contact
- Número de telefone: 248-858-6215
- E-mail: Emily.Crofts@trinity-health.org
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Saginaw, Michigan, Estados Unidos, 48604
- Suspenso
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Estados Unidos, 48601
- Recrutamento
- MyMichigan Medical Center Saginaw
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Tawas City, Michigan, Estados Unidos, 48764
- Recrutamento
- MyMichigan Medical Center Tawas
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
West Branch, Michigan, Estados Unidos, 48661
- Suspenso
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Estados Unidos, 48106
- Recrutamento
- Huron Gastroenterology PC
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Elie G. Dib
-
-
Minnesota
-
Burnsville, Minnesota, Estados Unidos, 55337
- Suspenso
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Estados Unidos, 55337
- Suspenso
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Estados Unidos, 55008
- Suspenso
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Recrutamento
- Mercy Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Edina, Minnesota, Estados Unidos, 55435
- Suspenso
- Fairview Southdale Hospital
-
Edina, Minnesota, Estados Unidos, 55435
- Recrutamento
- Minnesota Oncology - Edina
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Fridley, Minnesota, Estados Unidos, 55432
- Ativo, não recrutando
- Unity Hospital
-
Maple Grove, Minnesota, Estados Unidos, 55369
- Suspenso
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Estados Unidos, 55109
- Recrutamento
- Minnesota Oncology Hematology PA-Maplewood
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Maplewood, Minnesota, Estados Unidos, 55109
- Suspenso
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Suspenso
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Suspenso
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Suspenso
- Health Partners Inc
-
Monticello, Minnesota, Estados Unidos, 55362
- Suspenso
- Monticello Cancer Center
-
New Ulm, Minnesota, Estados Unidos, 56073
- Suspenso
- New Ulm Medical Center
-
Princeton, Minnesota, Estados Unidos, 55371
- Suspenso
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- Suspenso
- North Memorial Medical Health Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic in Rochester
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Investigador principal:
- Lance C. Pagliaro
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Recrutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Recrutamento
- Regions Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55102
- Suspenso
- United Hospital
-
Shakopee, Minnesota, Estados Unidos, 55379
- Suspenso
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Estados Unidos, 55082
- Recrutamento
- Lakeview Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Waconia, Minnesota, Estados Unidos, 55387
- Suspenso
- Ridgeview Medical Center
-
Willmar, Minnesota, Estados Unidos, 56201
- Suspenso
- Rice Memorial Hospital
-
Woodbury, Minnesota, Estados Unidos, 55125
- Recrutamento
- Minnesota Oncology Hematology PA-Woodbury
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Wyoming, Minnesota, Estados Unidos, 55092
- Suspenso
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Estados Unidos, 63011
- Suspenso
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Estados Unidos, 65613
- Suspenso
- Central Care Cancer Center - Bolivar
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Recrutamento
- Saint Francis Medical Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 573-334-2230
- E-mail: sfmc@sfmc.net
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Suspenso
- Mercy Cancer Center - Cape Girardeau
-
Farmington, Missouri, Estados Unidos, 63640
- Recrutamento
- Parkland Health Center - Farmington
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
Jefferson City, Missouri, Estados Unidos, 65109
- Suspenso
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Estados Unidos, 64804
- Suspenso
- Freeman Health System
-
Joplin, Missouri, Estados Unidos, 64804
- Suspenso
- Mercy Hospital Joplin
-
Rolla, Missouri, Estados Unidos, 65401
- Suspenso
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Estados Unidos, 65401
- Suspenso
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Suspenso
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Recrutamento
- Sainte Genevieve County Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
Springfield, Missouri, Estados Unidos, 65804
- Suspenso
- Mercy Hospital Springfield
-
Springfield, Missouri, Estados Unidos, 65807
- Suspenso
- CoxHealth South Hospital
-
St Louis, Missouri, Estados Unidos, 63128
- Recrutamento
- Mercy Hospital South
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
St Louis, Missouri, Estados Unidos, 63141
- Recrutamento
- Mercy Hospital Saint Louis
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 314-251-7066
-
St Louis, Missouri, Estados Unidos, 63109
- Suspenso
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Estados Unidos, 63131
- Recrutamento
- Missouri Baptist Medical Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
Sullivan, Missouri, Estados Unidos, 63080
- Recrutamento
- Missouri Baptist Sullivan Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 314-996-5569
-
Washington, Missouri, Estados Unidos, 63090
- Suspenso
- Mercy Hospital Washington
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- Suspenso
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89183
- Suspenso
- OptumCare Cancer Care at Fort Apache
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Concluído
- Hackensack University Medical Center
-
Livingston, New Jersey, Estados Unidos, 07039
- Recrutamento
- Cooperman Barnabas Medical Center
-
Investigador principal:
- Saum B. Ghodoussipour
-
Contato:
- Site Public Contact
- Número de telefone: 973-322-5200
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Recrutamento
- Rutgers Cancer Institute of New Jersey
-
Investigador principal:
- Saum B. Ghodoussipour
-
Contato:
- Site Public Contact
- Número de telefone: 732-235-7356
-
Toms River, New Jersey, Estados Unidos, 08755
- Recrutamento
- Community Medical Center
-
Investigador principal:
- Saum B. Ghodoussipour
-
Contato:
- Site Public Contact
- Número de telefone: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Recrutamento
- University of New Mexico Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 505-925-0348
- E-mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Investigador principal:
- Amy C. Tarnower
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Ativo, não recrutando
- Roswell Park Cancer Institute
-
-
North Carolina
-
Clinton, North Carolina, Estados Unidos, 28328
- Recrutamento
- Southeastern Medical Oncology Center-Clinton
-
Contato:
- Site Public Contact
- Número de telefone: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Investigador principal:
- Samer S. Kasbari
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Recrutamento
- Southeastern Medical Oncology Center-Goldsboro
-
Contato:
- Site Public Contact
- Número de telefone: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Investigador principal:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Recrutamento
- Southeastern Medical Oncology Center-Jacksonville
-
Investigador principal:
- Samer S. Kasbari
-
Contato:
- Site Public Contact
- Número de telefone: 910-587-9084
- E-mail: jfields@cancersmoc.com
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Ativo, não recrutando
- Wake Forest University Health Sciences
-
-
Ohio
-
Centerville, Ohio, Estados Unidos, 45459
- Recrutamento
- Miami Valley Hospital South
-
Contato:
- Site Public Contact
- Número de telefone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Investigador principal:
- Tarek M. Sabagh
-
Centerville, Ohio, Estados Unidos, 45459
- Ativo, não recrutando
- Dayton Physicians LLC-Miami Valley South
-
Dayton, Ohio, Estados Unidos, 45409
- Recrutamento
- Miami Valley Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Investigador principal:
- Tarek M. Sabagh
-
Dayton, Ohio, Estados Unidos, 45415
- Recrutamento
- Miami Valley Hospital North
-
Contato:
- Site Public Contact
- Número de telefone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Investigador principal:
- Tarek M. Sabagh
-
Dayton, Ohio, Estados Unidos, 45409
- Recrutamento
- Premier Blood and Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 937-276-8320
-
Investigador principal:
- Tarek M. Sabagh
-
Dayton, Ohio, Estados Unidos, 45415
- Ativo, não recrutando
- Dayton Physician LLC - Englewood
-
Findlay, Ohio, Estados Unidos, 45840
- Ativo, não recrutando
- Armes Family Cancer Center
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Recrutamento
- Atrium Medical Center-Middletown Regional Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Investigador principal:
- Tarek M. Sabagh
-
Franklin, Ohio, Estados Unidos, 45005
- Ativo, não recrutando
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Estados Unidos, 45331
- Recrutamento
- Miami Valley Cancer Care and Infusion
-
Investigador principal:
- Tarek M. Sabagh
-
Contato:
- Site Public Contact
- Número de telefone: 937-569-7515
-
Kettering, Ohio, Estados Unidos, 45409
- Ativo, não recrutando
- Greater Dayton Cancer Center
-
Kettering, Ohio, Estados Unidos, 45429
- Ativo, não recrutando
- Kettering Medical Center
-
Springfield, Ohio, Estados Unidos, 45504
- Suspenso
- Springfield Regional Cancer Center
-
Sylvania, Ohio, Estados Unidos, 43560
- Recrutamento
- ProMedica Flower Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 419-824-1842
- E-mail: PCIOncResearch@promedica.org
-
Investigador principal:
- Jeffrey H. Muler
-
Troy, Ohio, Estados Unidos, 45373
- Recrutamento
- Upper Valley Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 937-528-2900
- E-mail: clinical.trials@daytonncorp.org
-
Investigador principal:
- Tarek M. Sabagh
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Recrutamento
- Cancer Centers of Southwest Oklahoma Research
-
Contato:
- Site Public Contact
- Número de telefone: 877-231-4440
-
Investigador principal:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma Health Sciences Center
-
Contato:
- Site Public Contact
- Número de telefone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Adanma Anji Ayanambakkam Attanathi
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Suspenso
- Mercy Hospital Oklahoma City
-
-
Pennsylvania
-
Erie, Pennsylvania, Estados Unidos, 16505
- Recrutamento
- UPMC Hillman Cancer Center Erie
-
Investigador principal:
- Leonard J. Appleman
-
Contato:
- Site Public Contact
- Número de telefone: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- Recrutamento
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Contato:
- Site Public Contact
- Número de telefone: 724-838-1900
-
Investigador principal:
- Leonard J. Appleman
-
Hershey, Pennsylvania, Estados Unidos, 17033-0850
- Recrutamento
- Penn State Milton S Hershey Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 717-531-3779
- E-mail: CTO@hmc.psu.edu
-
Investigador principal:
- Monika Joshi
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- Recrutamento
- UPMC Hillman Cancer Center - Monroeville
-
Investigador principal:
- Leonard J. Appleman
-
Contato:
- Site Public Contact
- Número de telefone: 412-864-7716
- E-mail: ClinicalResearchServices@upmc.edu
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Recrutamento
- Thomas Jefferson University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 215-600-9151
- E-mail: ONCTrialNow@jefferson.edu
-
Investigador principal:
- William J. Tester
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- University of Pennsylvania/Abramson Cancer Center
-
Investigador principal:
- Ronac Mamtani
-
Contato:
- Site Public Contact
- Número de telefone: 215-349-8245
- E-mail: PMCancerResearch@pennmedicine.upenn.edu
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- Recrutamento
- UPMC-Passavant Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 412-367-6454
-
Investigador principal:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Estados Unidos, 15243
- Recrutamento
- UPMC-Saint Clair Hospital Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 412-502-3920
-
Investigador principal:
- Leonard J. Appleman
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Recrutamento
- UPMC Hillman Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 412-647-8073
-
Investigador principal:
- Leonard J. Appleman
-
Washington, Pennsylvania, Estados Unidos, 15301
- Recrutamento
- UPMC Cancer Center-Washington
-
Contato:
- Site Public Contact
- E-mail: ecog.rss@jimmy.harvard.edu
-
Investigador principal:
- Leonard J. Appleman
-
West Reading, Pennsylvania, Estados Unidos, 19611
- Recrutamento
- Reading Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 610-988-9323
-
Investigador principal:
- Terrence P. Cescon
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Ativo, não recrutando
- Medical University of South Carolina
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Vitaly Margulis
-
Dallas, Texas, Estados Unidos, 75235
- Recrutamento
- Parkland Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Vitaly Margulis
-
Dallas, Texas, Estados Unidos, 75237
- Suspenso
- UT Southwestern Simmons Cancer Center - RedBird
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Vitaly Margulis
-
Richardson, Texas, Estados Unidos, 75080
- Recrutamento
- UT Southwestern Clinical Center at Richardson/Plano
-
Contato:
- Site Public Contact
- Número de telefone: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Investigador principal:
- Vitaly Margulis
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Recrutamento
- University of Washington Medical Center - Montlake
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- Petros Grivas
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- Fred Hutchinson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- Petros Grivas
-
-
West Virginia
-
Charleston, West Virginia, Estados Unidos, 25304
- Recrutamento
- Vandalia Health/CAMC Institute for Academic Medicine
-
Investigador principal:
- Kok Hoe Chan
-
Contato:
- Site Public Contact
- Número de telefone: 304-388-9944
- E-mail: CAMCClinicalTrials@vandaliahealth.org
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- Recrutamento
- ThedaCare Regional Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 920-364-3604
- E-mail: ResearchDept@thedacare.org
-
Investigador principal:
- Matthias Weiss
-
Burlington, Wisconsin, Estados Unidos, 53105
- Recrutamento
- Aurora Cancer Care-Southern Lakes VLCC
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Recrutamento
- Marshfield Medical Center-EC Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
Germantown, Wisconsin, Estados Unidos, 53022
- Recrutamento
- Aurora Health Care Germantown Health Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Grafton, Wisconsin, Estados Unidos, 53024
- Recrutamento
- Aurora Cancer Care-Grafton
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Recrutamento
- Aurora BayCare Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Recrutamento
- Aurora Cancer Care-Kenosha South
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Marinette, Wisconsin, Estados Unidos, 54143
- Recrutamento
- Aurora Bay Area Medical Group-Marinette
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Recrutamento
- Marshfield Medical Center-Marshfield
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Recrutamento
- Aurora Cancer Care-Milwaukee
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Recrutamento
- Aurora Saint Luke's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Recrutamento
- Aurora Sinai Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Recrutamento
- Marshfield Medical Center - Minocqua
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- Recrutamento
- ProHealth D N Greenwald Center
-
Contato:
- Site Public Contact
- E-mail: research.institute@phci.org
-
Investigador principal:
- Timothy R. Wassenaar
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Suspenso
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- Recrutamento
- ProHealth Oconomowoc Memorial Hospital
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-7878
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Recrutamento
- Vince Lombardi Cancer Clinic - Oshkosh
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Racine, Wisconsin, Estados Unidos, 53406
- Recrutamento
- Aurora Cancer Care-Racine
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Recrutamento
- Marshfield Medical Center-Rice Lake
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Recrutamento
- Vince Lombardi Cancer Clinic-Sheboygan
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Recrutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
Summit, Wisconsin, Estados Unidos, 53066
- Recrutamento
- Aurora Medical Center in Summit
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Recrutamento
- Vince Lombardi Cancer Clinic-Two Rivers
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Recrutamento
- ProHealth Waukesha Memorial Hospital
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-7632
-
Waukesha, Wisconsin, Estados Unidos, 53188
- Recrutamento
- UW Cancer Center at ProHealth Care
-
Investigador principal:
- Timothy R. Wassenaar
-
Contato:
- Site Public Contact
- Número de telefone: 262-928-5539
- E-mail: Chanda.miller@phci.org
-
Waupaca, Wisconsin, Estados Unidos, 54981
- Recrutamento
- ThedaCare Cancer Care - Waupaca
-
Contato:
- Site Public Contact
- Número de telefone: 920-364-3605
- E-mail: ResearchDept@thedacare.org
-
Investigador principal:
- Matthias Weiss
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Aurora Cancer Care-Milwaukee West
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
West Allis, Wisconsin, Estados Unidos, 53227
- Recrutamento
- Aurora West Allis Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 414-302-2304
- E-mail: ncorp@aurora.org
-
Investigador principal:
- Thomas J. Saphner
-
Weston, Wisconsin, Estados Unidos, 54476
- Recrutamento
- Marshfield Medical Center - Weston
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Seth O. Fagbemi
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
STEP 1 REGISTRATION AND RANDOMIZATION
-
Patients must be >= 18 years of age
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible
-
Patient must have a diagnosis of high grade upper tract urothelial carcinoma expected within 14 weeks (98 days) prior to registration/randomization with one of the following:
-
Biopsy (gold standard, preferred) and either upper urinary tract mass on cross-sectional imaging or tumor directly visualized during upper urinary tract endoscopy
-
High grade cytology and clinically estimated invasive upper urinary tract mass on cross-sectional imaging (e.g., including presence of tumor-related hydronephrosis) or tumor directly visualized during upper urinary tract endoscopy
-
NOTE: Universal histologic testing of UTUC with additional studies, such as immunohistochemistry and/or microsatellite instability, is strongly recommended to identify patients with high probability of Lynch-related or other germline mutation related cancers whom clinicians should refer for genetic counseling and germline testing (this is not required for eligibility)
- Due to the anatomy of upper urinary tract and lack of muscularis propria, pathologic evidence of cT2 on biopsy is usually not possible
-
-
-
Patients must not have any component of small cell/neuroendocrine carcinoma. Other histologic subtypes (variants) are permitted provided the half or predominant (>= 50%) subtype is conventional urothelial carcinoma
-
Leukocytes >= 3,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Platelets >= 100,000/mcL (obtained =< 14 days prior to registration/randomization)
-
Total bilirubin =< 1.2 mg/dL (or ≤ 2 mg/dL for patients with Gilbert's disease)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN (obtained =< 14 days prior to registration/randomization)
-
Hemoglobin (Hgb) >= 9 g/dL (obtained =< 14 days prior to registration/randomization)
- NOTE: Packed red blood transfusion is allowed to achieve this parameter as per treating investigator
-
Patients must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy. A patient of childbearing potential is defined as any patient, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
-
Patients of childbearing potential and sexually active patients must not expect to conceive or father children, either by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of registration, while on study treatment and for at least 6 months after the last dose of protocol treatment
-
Patients must have no evidence of metastatic disease or clinically enlarged regional lymph nodes (>= 1.5 cm short axis) on imaging required within 28 days prior to registration (Non-regional findings >=1.5 cm short axis that in the opinion of the investigator are not concerning for involvement based on radiographic characteristics, chronicity, avidity on positron emission tomography (PET) scan or other imaging or other criteria can be eligible based on investigator discretion).
- NOTE: Patients with elevated alkaline phosphatase, calcium or suspicious bone pain/tenderness can also undergo baseline bone scan to evaluate for bone metastasis at the discretion of local provider.
-
Patient must meet below criteria for prior/current malignancy history:
-
Non-urothelial cancer malignancy history:
-
Patient must not have another active (or within two years) second malignancy other than resected non-melanoma skin cancers, resected in situ breast, cervical or other in situ carcinoma, and either clinically insignificant per the investigator (e.g. =< Gleason 3+4) on active surveillance (or watchful waiting) or previously treated prostate cancer with no rising prostate specific antigen (PSA) and no plan to treat
- NOTE: Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Urothelial cancer malignancy history:
- Patient may have a history of resectable urothelial cancer as long as patients meet one of the following:
- T0, Ta or Tis at any time
- T1-4a N0 and no evidence of disease (NED) for more than 2 years from the latest therapy [e.g., radical surgery, transurethral resection of bladder tumor (TURBT), radiation, chemotherapy (neoadjuvant or adjuvant, or with radiation)]. Prior systemic immune checkpoint inhibitor is not allowed.
- Patient with history of >= pT4b, N+, and/or M1 UC is not eligible.
- NOTE: Patients in whom concomitant or prior bladder/urethra predominant (>= 50%) urothelial carcinoma have been surgically resected and demonstrated to be only Ta or carcinoma in situ (CIS) (< cT1 N0) are eligible regardless of time elapsed
-
-
-
Patient must not have any uncontrolled illness including, but not limited to, ongoing or active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), symptomatic congestive heart failure (CHF), myocardial infarction (MI) or unstable angina pectoris, significant uncontrolled cardiac arrhythmia, clinically relevant liver cirrhosis, interstitial lung disease, or psychiatric illness/social situations in the three months prior to registration that would limit compliance with study requirements
-
Patient must not have received prior radiation therapy to >= 25% of the bone marrow for other diseases
-
Patient must not have received prior systemic anthracycline therapy
- NOTE: Patients who have received prior intravesical therapy at any time for non-muscle invasive urothelial carcinoma of the bladder are eligible
-
Patient must not have either history of or active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration/randomization or any history of inflammatory bowel disease (inflammatory bowel disease [IBD], e.g. ulcerative colitis, or Crohn's disease), neuromuscular autoimmune condition, immune-related pneumonitis or interstitial lung disease. Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diabetes mellitus type I, vitiligo, alopecia, psoriasis, eczema, lichen planus, or similar skin/mucosa condition are eligible
-
Patient must not be on or have used immunosuppressive medication within 14 days prior to the first dose of durvalumab. The following are exceptions to this criterion and are allowed:
- Intranasal, inhaled, intra-auricular, topical steroids, or local steroid injections (e.g. intra-articular injection
- Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent at the time of enrollment
- Steroids as pre-medications for hypersensitivity reactions (e.g. computed tomography [CT] pre-medication)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration/randomization are eligible for this trial
- NOTE: These patients must be stable on their anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on the same regimen; the most recent undetectable viral load must be within the past 12 weeks. They must have a CD4 count of greater than 250 cells/mcL over the past 6 months on this same anti-retroviral regimen and must not have had a CD4 count < 200 cells/mcL over the past 2 years, unless it was deemed related to the cancer and/or chemotherapy induced bone marrow suppression. They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
- NOTE: For patients who have received chemotherapy in the past 6 months, a CD4 count < 250 cells/mcL during chemotherapy is permitted as long as viral loads were undetectable during this same chemotherapy. They must have an undetectable viral load and a CD4 count >= 250 cells/mcL within 7 days of registration/randomization
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- NOTE: Testing for HIV, hepatitis B or hepatitis C is not required unless clinically indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and have undetectable viral load. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
Patient must not have received live attenuated vaccine within 30 days prior to the first dose of durvalumab, while on protocol treatment and within 30 days after the last dose of durvalumab
-
Patient must not have had a major surgical procedure within 28 days prior to registration/randomization
- NOTE: Cystoscopy/ureteroscopy/TURBT, stent placement or nephrostomy tube is not considered major surgery
-
Patient must not have history of allogenic organ transplantation
-
Patient must have a body weight of > 30 kg
-
Patient must have life expectancy of >= 12 weeks
-
Patient must have creatinine clearance > 15 ml/min as estimated by Cockcroft-Gault formula or glomerular filtration rate (GFR) > 15 ml/min/1.73m^2 within 28 days prior to registration/randomization
-
NOTE: Patients will be assigned to cisplatin-ineligible and cisplatin-eligible cohorts based on their creatinine clearance, Eastern Cooperative Oncology Group (ECOG) performance status, and grade (if any) of peripheral neuropathy and/or hearing loss in keeping with recommended cisplatin contraindications. Patients who are cisplatin-eligible will be randomized to either Arm A or Arm B and patients who are cisplatin-ineligible will be registered to Arm C
-
Patients that meet any of the following four criteria will be registered to the cisplatin-ineligible Arm C if they meet other eligibility criteria:
- Creatinine clearance > 15 ml/min and =< 50 ml/min (estimated by Cockcroft-Gault formula) or GFR > 15ml/min/1.73m^2 and ≤ 50 ml/min/1.73 m^2
- Hearing loss >= 3
- Neuropathy >= 2
- ECOG performance status 2
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,000/mcL obtained =< 14 days prior to registration
-
Patients that meet all of the following four criteria will be randomized to the cisplatin-eligible Arm A or Arm B:
- Creatinine clearance > 50ml/min (estimated by Cockcroft-Gault formula) or GFR > 50ml/min/1.73m^2
- ECOG performance status 0-1
- Hearing loss grade 0-2
- Neuropathy 0-1
-
In addition, the patient must have an absolute neutrophil count (ANC) >= 1,500/mcL obtained =< 14 days prior to randomization
-
Also, the patient must have left ventricular ejection fraction (LVEF) >= 50% by (either multigated acquisition scan [MUGA] or 2-D echocardiogram) obtained within obtained within 28 days prior to randomization
-
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm A (durvalumab, chemotherapy)
Patients receive durvalumab IV over 60 minutes on day 1 of chemotherapy cycles 1 and 3. Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Given IV
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Undergo surgery Undergo tissue biopsy
Outros nomes:
Given IV
Outros nomes:
Given Iv
Outros nomes:
Given via injection
Outros nomes:
Given Iv
Outros nomes:
|
|
Comparador Ativo: Arm B (chemotherapy)
Patients also receive methotrexate IV over 2-3 minutes, vinblastine sulfate IV, doxorubicin IV, cisplatin IV over at least 2 hours on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Given IV
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Undergo surgery Undergo tissue biopsy
Outros nomes:
Given Iv
Outros nomes:
Given via injection
Outros nomes:
Given Iv
Outros nomes:
|
|
Experimental: Arm C (durvalumab, gemcitabine hydrochloride)
Patients receive durvalumab IV over 60 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Within 21- 60 days after completion of systemic treatment, patients with continued lack of radiographic presence of metastatic or unresectable disease undergo surgery. Patients also undergo tissue biopsy and blood sample collection on study, and CT or MRI throughout the trial. |
Undergo blood sample collection
Outros nomes:
Undergo CT
Outros nomes:
Undergo MRI
Outros nomes:
Given IV
Outros nomes:
Undergo surgery Undergo tissue biopsy
Outros nomes:
Given IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Event-free survival (EFS) (Cisplatin eligible cohort: Arms A and B)
Prazo: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Disease progression prior to surgery or omission of surgery due to unresectable tumors, muscle-invasive cancer or disease recurring outside of the bladder, urethra, or contralateral upper tract are considered as events for EFS. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Pathologic complete response (pCR) (Cisplatin ineligible cohort: Arm C)
Prazo: At surgery
|
Will assess pathologic complete response at surgery (pCR, pT0N0/Nx) by local pathology review. Patients who drop out prior to surgery or who have unknown response status will be considered as non-responders. |
At surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
pCR (coorte elegível para cisplatina: Braços A e B)
Prazo: Até 5 anos
|
Até 5 anos
|
|
|
EFS (cisplatin-ineligible cohort: Arm C)
Prazo: From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
Will be characterized using the Kaplan-Meier method. |
From registration/randomization to the earliest of systemic recurrence outside urinary tract, cancer progression, or death from any cause, assessed up to 5 years
|
|
Overall survival (OS) (All Patients)
Prazo: From registration/randomization to death from any cause, assessed up to 5 years
|
OS will be evaluated by arm, post chemotherapy response (ypCR, stage yp =< T1N0, yp >= T2N0), as well as stage (ypCR and > ypCR) within and across treatment arms. Will be estimated using Kaplan-Meier method. |
From registration/randomization to death from any cause, assessed up to 5 years
|
|
Urothelial cancer-free survival or disease-free survival (All Patients)
Prazo: From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
A return of UTUC includes non-muscle invasive recurrences, pathologic T2 or higher muscle-invasive recurrences specifically in the urinary tract, metastatic disease outside the urinary tract, or death. Patients alive without documented UTUC will be censored at the date of last disease assessment. |
From the date of surgery to the earlier of a return of upper tract urothelial cancer (UTUC) or death from any cause, assessed up to 5 years
|
|
Cancer-specific survival (All Patients)
Prazo: From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
Will be analyzed using Gray's method and cumulative incidence estimates will be reported. |
From registration/randomization to death due to cancer; deaths due to other causes will be counted as competing events, assessed up to 5 years
|
|
Renal function outcomes following systemic treatment and following radical nephroureterectomy (All Patients)
Prazo: Post chemotherapy and post surgery
|
The proportion of patients with renal insufficiency (creatinine [CrCl] < 60 ml/min) post chemotherapy and post nephroureterectomy as well as the proportion of patients with renal function improvement (CrCl < 60 ml/min at baseline and CrCl >= 60 ml/min on study) will be reported along with exact binomial confidence intervals. The distribution of changes in renal function post chemotherapy as well as post surgery from baseline will also be reported. The analysis of renal function outcomes will be performed among patients who receive at least one dose of study therapy. |
Post chemotherapy and post surgery
|
|
Incidence of adverse events (All Patients)
Prazo: Up to 30 days post surgery
|
Toxicity will be evaluated in all treated patients. |
Up to 30 days post surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jean H Hoffman-Censits, ECOG-ACRIN Cancer Research Group
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos de enxofre
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Técnicas citológicas
- Citodiagnóstico
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Carboidratos
- Alcalóides
- Hidrocarbonetos aromáticos policíclicos
- Hidrocarbonetos, aromáticos
- Compostos policíclicos
- Glicosídeos
- Indoles
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Elementos
- Metais
- Técnicas de diagnóstico, cirúrgico
- Técnicas de química, analíticas
- Análise de espectro
- Pterins
- Pteridinas
- Metais, pesados
- Alcalóides de Vinca
- Alcalóides de triptamina de secologanin
- Alcalóides indol
- Indolizidinas
- Indolizinas
- Aminopterina
- Antraciclinas
- Nafthacenos
- Aminoglicosídeos
- Isotipos de imunoglobulina
- Sulfetos
- Ânions
- Íons
- Eletrólitos
- Sulfeto de hidrogênio
- Compostos de platina
- Daunorubicina
- Elementos de transição
- Gemcitabina
- Metotrexato
- Doxorrubicina
- Imunoglobulina G
- Cisplatina
- Vinblastina
- Citrato de 1,2-diaminociclohexanoplatina II
- Biópsia
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- durValumab
- Dissulfetos
- Platina
- Merphos
- pegfilgrastim
- fator estimulador de colônias de granulócitos peguilados
Outros números de identificação do estudo
- NCI-2020-09850
- U10CA180820 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-09850 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EA8192 (Outro identificador: CTEP)
- EA8192 (Outro identificador: ECOG-ACRIN Cancer Research Group)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .